Skip to main content
Delfa

← All assets

Aducanumab

10 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

10

Ongoing

0

Recruiting

0

Completed

4

Sites

634

Countries

22

Endpoints

142

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 142 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
4
Phase 2
1
Phase 3
5

Trials by status

Completed
4
Terminated
6

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Amyloid biomarkers
48
Other (unclassified)
28
Global cognition
24
Safety / tolerability / PK
21
Neuroimaging
9
Function / daily living
8
Behavior / neuropsychiatric
2
Tau biomarkers
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 72 of 142 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Amyloid PET CentiloidAmyloid

38

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

8

ADAS-CogCognition

8

Mini-Mental State Examination (MMSE)Cognition

6

ADCS-Activities of Daily Living (ADCS-ADL)Function

6

ADAS-CogFunction

2

Neuropsychiatric Inventory (NPI)Behavior

2

Montreal Cognitive Assessment (MoCA)Cognition

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

10 of 10

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT04241068A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

Aducanumab

Alzheimer’s disease

Age 50-90Ph 3Terminated297Jul 2024-results
ENVISIONA Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Aducanumab

Alzheimer’s disease

MCI due to ADPh 3Terminated265Aug 2024-results
ENGAGE221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

Aducanumab

Alzheimer’s disease

MCI due to ADPh 3Terminated181Aug 20193results
EMERGE221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

Aducanumab

Alzheimer’s disease

MCI due to ADPh 3Terminated180Aug 20195results
PRIMEMultiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease

Aducanumab

Alzheimer’s disease

prodromal ADPh 1Terminated32Jul 20192
NCT05108922A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

Aducanumab, Donanemab

Alzheimer’s disease, MCI / preclinical Alzheimer’s

MMSE 20-30Ph 3Completed31Sep 20222results
EVOLVEA Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

Aducanumab

Alzheimer’s disease, MCI / preclinical Alzheimer’s

MCI due to AD / mild AD dementiaPh 2Terminated22Jul 2019-results
PROPELSingle and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease

Aducanumab

Alzheimer’s disease

mild-to-moderate ADPh 1Completed7Dec 2016-
NCT01397539Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease

Aducanumab

Alzheimer’s disease

Alzheimer's diseasePh 1Completed3Aug 20131
NCT02782975Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants

Aducanumab

Alzheimer’s disease

Age 18-55Ph 1Completed2Nov 2016-

Showing 1-10 of 10 trials